Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease
- Author:
So My KOO
1
;
Song Yee KIM
;
Sun Mi CHOI
;
Hyun Kyung LEE
;
Author Information
- Publication Type:Randomized Controlled Trial
- Keywords: Lung Disease, Interstitial; Connective Tissue Disease; Asian Continental Ancestry Group; Guidelines as Topic; Diagnosis; Disease Management; Lung
- MeSH: Arthritis, Rheumatoid; Asian Continental Ancestry Group; Autoantibodies; Connective Tissue Diseases; Connective Tissue; Diagnosis; Disease Management; Guidelines as Topic; Humans; Idiopathic Interstitial Pneumonias; Incidence; Lung; Lung Diseases, Interstitial; Myositis; Prognosis; Scleroderma, Systemic; Thorax
- From:Tuberculosis and Respiratory Diseases 2019;82(4):285-297
- CountryRepublic of Korea
- Language:English
- Abstract: Connective tissue disease (CTD) is a collection of disorders characterized by various signs and symptoms such as circulation of autoantibodies in the entire system causing damage to internal organs. Interstitial lung disease (ILD) which is associated with CTD is referred to as CTD-ILD. Patients diagnosed with ILD should be thoroughly examined for the co-occurrence of CTD, since the treatment procedures and prognosis of CTD-ILD are vary from those of idiopathic interstitial pneumonia. The representative types of CTD which may accompany ILD include rheumatoid arthritis, systemic sclerosis (SSc), Sjögren's syndrome, mixed CTD, idiopathic inflammatory myopathies, and systemic lupus erythematous. Of these, ILD most frequently co-exists with SSc. If an ILD is observed in the chest, high resolution computed tomography and specific diagnostic criteria for any type of CTD are met, then a diagnosis of CTD-ILD is made. It is challenging to conduct a properly designed randomized study on CTD-ILD, due to low incidence. Therefore, CTD-ILD treatment approach is yet to been established in absence of randomized controlled clinical trials, with the exception of SSc-ILD. When a patient is presented with acute CTD-ILD or if symptoms occur due to progression of the disease, steroid and immunosuppressive therapy are generally considered.
